Fine-needle aspiration cytology (FNAC) is essential for making a diagnosis in advanced breast cancer. The determination of hormone receptors in the material obtained is useful for predicting patient response to endocrine therapy, but the prognostic value of hormone receptor expression as well as the clinical utility of DNA flow cytometry are controversial. The aim of this prospective study with long-term follow-up (median: 81 months) was to evaluate these biomarkers in relation to overall survival in a series of 392 patients with advanced breast cancer (stage IIB, n=106; IIIA, n=66; IIIB, n=174; and IV, n=46) using FNAC. Estrogen and progesterone receptor expression was found in 65.1% and 46.1% of the tumors, respectively. Hormone receptors were not found to be associated with clinical staging. DNA aneuploidy was present in 70.9% of the cases and the median S-phase fraction (SPF) was 9.4%. There was a significant correlation of aneuploidy and high SPF with lack of hormone receptors. In univariate analysis, advanced disease stage, absence of hormone receptors, DNA aneuploidy and high SPF showed a statistically significant correlation with poor clinical outcome. In multivariate analysis, disease stage, progesterone receptors and DNA ploidy retained independent prognostic significance in relation to overall survival. These data indicate that progesterone receptor expression and DNA ploidy are independent prognostic factors in advanced breast cancer. (Int J Biol Markers 2003; 18: 7-12)
INTRODUCTION
Despite the screening mammography programs implemented in recent years (1, 2) there is a non-negligible number of cases of locally advanced and metastatic breast cancer, found ab initio, that still constitutes a relevant cause of oncological mortality. In our department the primary diagnosis of these patients is routinely made by fine-needle aspiration cytology (FNAC) (3), a technique that allows to obtain simultaneously biological material for hormone receptor assays and DNA flow cytometry (4) (5) (6) (7) (8) .
The predictive value of hormone receptor status for the patient's response to endocrine therapy has been generally recognized, but its prognostic significance in relation to disease outcome appears less clear. Likewise, the currently available data are still insufficient to recommend the application of DNA flow cytometric parameters in clinical practice, due mainly to the lack of methodological standardization (9) . Furthermore, the earlier detection of primary breast carcinomas has contributed to decreased attention for the clinical aspects of advanced breast cancer, thus leading to less consistent prognostic information.
The aim of this prospective study with long-term follow-up of a large series of patients with advanced breast cancer was to evaluate the independent prognostic value of hormone receptor expression and DNA flow cytometry (ploidy and S-phase) using FNAC.
MATERIAL AND METHODS
The study group consisted of 392 women with locally advanced or metastatic breast carcinoma diagnosed at the Cytology Service of the Portuguese Oncological Institute (Lisbon) between October 1991 and December 1995. The median age of the patients was 63 years (mean 61.5; range 24-91). None had received any treatment prior to admission. Disease stage was defined according to the TNM-UICC classification system (10) . The series included patients at several advanced clinical stages of the disease: stage IIB (n=106), stage IIIA (n=66), stage IIIB (n=174), and stage IV (n=46).
Fine-needle aspiration cytology was performed in each patient using a 23-gauge needle attached to a 10-mL syringe. Part of the material obtained was handled as a standard routine aspirate to make the cytological diagnosis. Air-dried smears were obtained for both May-Grünwald-Giemsa staining and immunocytochemical assay of hormone receptors. The remaining material was expelled into a tube containing 2 mL of phosphate buffered saline (PBS) and immediately sent to the flow cytometry laboratory for DNA analysis.
The therapeutic schemes used were available for 372 patients; 175 of them (47%) were submitted to surgical treatment (172 mastectomies and 3 tumorectomies) and 197 (53%) received no surgery. Neoadjuvant therapy was administered to 142 patients, 75 of whom receiving chemotherapy. In the subgroup of patients who did not undergo surgery 99 were given chemotherapy and 113 hormone therapy (tamoxifen). In the whole series, 312 of 372 patients (83.9%) were submitted to some kind of combined therapy.
Clinical outcome was assessed in terms of overall survival, that is, the interval between diagnosis and the last clinical observation or death. Survival information was obtained from review of clinical records or consultation with the epidemiological registry service at our institution (ROR-Sul). Data from patients who did not die of the disease were used as censored data for the determination of follow-up time and survival analysis.
Hormone receptor assays
Estrogen receptors (ER) and progesterone receptors (PgR) were analyzed by immunocytochemistry on cytological smears using the peroxidase-antiperoxidase PAP technique (11) (prediluted kits ER-ICA and PgR-ICA monoclonal; Abbott Laboratories, Chicago, IL, USA) according to the manufacturer's protocol. A blocking reagent was used to prevent nonspecific binding. Anti-ER and anti-PgR rat monoclonal antibodies and a goat anti-rat IgG were applied as primary and secondary antibodies, respectively. The incubation with PAP complex was visualized by a chromogen substrate solution containing hydrogen peroxide and diaminobenzidine, followed by Harris hematoxylin counterstaining. Breast cancer tissue known to be ER and PgR positive was included as positive control with each assay run. The results were recorded as the percentage of positively stained malignant cells; specimens showing more than 10% stained nuclei were considered positive (12) .
DNA flow cytometry
The fine-needle aspirates were immediately processed for DNA flow cytometric analysis (13) . The cell suspension obtained was rinsed twice in PBS and the representativity of the sample was checked by counting the cells in a Bürker hemocytometer. For DNA staining, the cells were treated with 1 mg/mL ribonuclease in PBS and 0.05% Nonidet P40 non-ionic detergent, and incubated with 50 µg/mL propidium iodide (PI) in Tris/MgCl 2 buffer, for one hour at 4°C protected from light. Before flow cytometric analysis the specimens were syringed through a 27-gauge needle and then sieved through a 55-µm nylon mesh. The samples were analyzed on an Epics Profile II flow cytometer (Coulter Electronics, Hialeah, FL, USA) equipped with a 488 nm, 15 mW argon ion laser as light source and a 575 band-pass filter for PI detection. Fluorescent beads (DNA-Check; Coulter) were used for instrument alignment, and chicken erythrocytes were added to each sample as internal standard. DNA histograms were analyzed using the Multicycle Program (Phoenix Flow Systems, San Diego, CA, USA), a software that includes a multiple option cell cycle fitting that automatically determines the DNA index and cell cycle phase fractions (14) . The tumors were classified dichotomously (diploid vs. aneuploid) according to the DNA ploidy pattern. The coefficient of variation of tumor G 0 /G 1 peaks, estimated as half peak width, ranged from 2.6% to 6.9% (mean, 4.3%). The internal reference standard consisted of mixed "non-malignant" diploid cells within the tumor sample analyzed. The Sphase fraction (SPF) was determined using the Multicycle zero order S-phase calculation and "sliced nuclei" debris option with aggregate correction (15), a polynomial model that allowed SPF determination in 237 tumors (60.5%). In the remaining cases, SPF could not be reliably assessed because of high background debris (cutoff >20%), overlap of populations, and/or insufficient amount of cells for analysis (16) (17) (18) . There were no differences between the characteristics of the cases in which SPF was or was not determined. For survival analysis SPF was investigated either as a continuous variable (% absolute values) or by using the median value as cutoff to classify tumors by their proliferative activity.
Statistical analysis
Correlations between variables were analyzed using the chi-square test. Overall survival was estimated according to the Kaplan-Meier method (19) and the differences between survival curves were evaluated by the log-rank test (20) . Univariate and multiple Cox regression models were calculated to identify prognostic factors and to determine the patient's risk of dying (21) . The statistical significance was assessed using the Wald test and results were displayed as relative risk and respective 95% confidence intervals for each category. P values less than 0.05 were considered significant.
RESULTS
ER and PgR assays were positive in 235 of 361 (65.1%) and 166 of 360 (46.1%) tumors, respectively. The remaining cases lacked representative material. No significant correlation between hormone receptor expression and clinical stage was found (p=0.148 and p=0.134).
Of the 392 breast tumors analyzed by flow cytometry, 114 (29.1%) showed a diploid DNA pattern and 278 (70.9%) were DNA aneuploid. The median SPF value of the tumors (n=37) in which SPF determination was feasible was 9.4%, ranging from 0.5% to 26.7%. This value was used for discriminating between tumors with low proliferative activity (<9.4%) and tumors with high proliferative activity (≥9.4%). A statistically significant correlation between DNA aneuploidy and high SPF was observed (p<0.001). Table I shows the correlations of clinical stage and hormone receptor expression with flow cytometric parameters in advanced breast carcinoma. DNA aneuploidy and high proliferative activity were significantly associated with lack of hormone receptors, but no differences in relation with disease stage were observed.
The median follow-up in this study was 81 months (range 3-117). At the end of the follow-up period 102 pa- In multivariate analysis, a first step excluded SPF because it did not reach statistical significance; in a second step, it was found that ER did not satisfy the proportional hazards function. Therefore, the multivariate model used in our study included the remaining variables stratified by ER. Table III illustrates the final results obtained from this multivariate analysis, in which 34 cases were considered as missing data. SPF was also assessed without any a priori classification by using it as a continuous variable, but, although showing statistical significance in univariate analysis (p = 0.002), it lost prognostic value in multivariate analysis.
DISCUSSION
Despite the extensive literature on the topic, the prognostic value of hormone receptor status and DNA flow cytometry in breast cancer is not yet clearly established. This prospective study was designed in an attempt to provide the requisites for a powerful statistical analysis, including a large number of patients and events and an adequate follow-up period. Moreover, the use of fresh FNAC material could overcome several sampling disaggregation problems related to the flow cytometry technique.
Since 62.5% of our patients died of the disease during follow-up, our data confirmed the already known poor prognosis of patients with locally advanced or metastatic breast carcinoma (22) . However, significant differences were observed in patient survival relative to the stage of the disease, which confirms that clinical stage is a major determinant of prognosis ( Fig. 1 ). In agreement with most studies (23), a strong positive correlation between DNA ploidy and S-phase fraction and an inverse correlation between the latter two parameters and hormone receptor expression were observed. In advanced breast cancer, like in the early stages of the disease (24) , DNA ploidy was found to be an independent indicator of prognosis. It should be noted that the incidence of aneuploidy (70.9%) and the median SPF (9.4%) found in the present study were higher than the values obtained by our group in a previously published report of early breast cancer (56.5% and 6.1%, respectively) (24) . This finding suggests that increased genomic instability and higher proliferative activity are typical features associated with more advanced stages of disease and the state of genetic tumor evolution. Moreover, it highlights the question of whether different SPF cutoff values depending on disease stage should be used for characterization of tumor proliferation and analysis of the prognostic relevance of SPF. However, the need for different cutoff values might be overcome by evaluating SPF as a con- (25, 26) . The latter approach was also investigated in the series, but, similar to using the median cutoff value to discriminate tumors, it could not demonstrate the independent prognostic value of SPF. This finding may be explained, at least in part, by the inability to determine SPF in a relatively high percentage of cases, a technical disadvantage inherent to this biomarker. Multivariate analysis showed that progesterone receptor status is an independent predictor of survival in advanced breast cancer. The clinical utility of estrogen receptor determination for therapeutic purposes by identifying patients that are most likely to benefit from hormonal therapies is well established (5, 27) . Some authors have even suggested that steroid receptor content should be analyzed on a continuous scale, instead of using arbitrary cutoffs, to improve the choice of adequate therapeutic strategies (28) . However, there are divergent views about the role played by hormone receptors in the prediction of disease outcome, mainly in early breast carcinoma where they are considered to have only limited prognostic value (29) (30) (31) . Our data suggest that hormone receptor analyses are clinically useful in the management of patients with advanced breast cancer, providing additional predictive information. The true magnitude of the prognostic capacity of ER expression is difficult to examine, since most patients with ER-positive tumors receive (neo)adjuvant hormonal therapy. In these circumstances the independent prognostic value of PgR analysis becomes a very important finding. It should be remembered that most patients with advanced breast cancer un-dergo various combinations of treatment modalities, and therapeutic heterogeneity may therefore influence the overall survival.
In conclusion, our findings indicate that progesterone receptor expression and DNA ploidy are independent prognostic factors in advanced breast cancer, the longterm overall survival being more favorable in patients with diploid PgR-positive tumors.
